Neurocrine Biosciences Inc. (NBIX)
NASDAQ · Healthcare
Neurocrine Biosciences Inc. Shareholder Equity 2009–2025
Neurocrine Biosciences Inc. annual/quarterly shareholder equity history from 2010 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Neurocrine Biosciences Inc. shareholder equity for the quarter ending December 31, 2025 were 3.25B, a 25.62% increase year-over-year.
- Neurocrine Biosciences Inc. shareholder equity for 2025 were 3.25B, a 25.62% increase from 2024.
- Neurocrine Biosciences Inc. shareholder equity for 2024 were 2.59B, a 16.03% increase from 2023.
- Neurocrine Biosciences Inc. shareholder equity for 2023 were 2.23B, a 30.69% increase from 2022.
- Neurocrine Biosciences Inc. shareholder equity for 2022 were 1.71B.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Neurocrine Biosciences Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $3,253 |
| 2024 | $2,590 |
| 2023 | $2,232 |
| 2022 | $1,708 |
| 2021 | $1,374 |
| 2020 | $1,126 |
| 2019 | $637 |
| 2018 | $481 |
| 2017 | $372 |
| 2016 | $315 |
| 2015 | $424 |
| 2014 | $209 |
| 2013 | $120 |
| 2012 | $154 |
| 2011 | $60 |
| Neurocrine Biosciences Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $3,253 |
| 2024-12-31 | $2,590 |
| 2023-12-31 | $2,232 |
| 2022-12-31 | $1,708 |
| 2021-12-31 | $1,374 |
| 2020-12-31 | $1,126 |
| 2019-12-31 | $637 |
| 2018-12-31 | $481 |
| 2017-12-31 | $372 |
| 2016-12-31 | $315 |
| 2015-12-31 | $424 |
| 2014-12-31 | $209 |
| 2013-12-31 | $120 |
| 2012-12-31 | $154 |
| 2011-12-31 | $60 |
| 2010-12-31 | $19 |
Neurocrine Biosciences Inc. Shareholder Equity — FAQ
Neurocrine Biosciences Inc. (NBIX) shareholder equity over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see NBIX's shareholder equity history?
The chart and table above show Neurocrine Biosciences Inc.'s shareholder equity by year and by quarter, including the growth rate.